Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/1997
10/28/1997CA2136825C Quaternary nitrogen-containing phosphonate compounds, for treating abnormal calcium and phosphate metabolism as well as dental calculus and plaque
10/25/1997CA2203466A1 Novel specific immunophilin ligands as antiasthmatics and immunosuppressants
10/23/1997WO1997039102A2 Secreted proteins
10/23/1997WO1997039032A1 Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
10/23/1997WO1997039001A1 Isoxazolidine derivatives
10/23/1997WO1997038993A1 Isatin derivatives as acetylcholinesterase inhibitors and analgesics
10/23/1997WO1997038992A1 Piperidinylpyramidine derivatives
10/23/1997WO1997038990A1 Novel n-aminoalkyl-1-biphenylenyl-2-carboxamides; new dopamine receptor subtype specific ligands
10/23/1997WO1997038989A1 N-aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
10/23/1997WO1997038986A1 Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
10/23/1997WO1997038983A1 Irreversible inhibitors of tyrosine kinases
10/23/1997WO1997038966A2 Cytoprotective compounds
10/23/1997WO1997038731A1 Immunoliposomes that optimize internalization into target cells
10/23/1997WO1997038729A1 In vivo gene transfer methods for wound healing
10/23/1997WO1997038708A1 Modulating epithelial-mesenchymal interactions
10/23/1997WO1997038705A1 N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
10/23/1997WO1997038699A2 Use of alkylaryl polyether alcohol polymers for the treatment of chronic pulmonary inflammation
10/23/1997WO1997038697A1 Sensitization of cells to radiation and chemotherapy
10/23/1997WO1997038690A1 Agent for inhibiting leukocyte invasion of tissues
10/23/1997WO1997038665A2 Inhibitors of farnesyl-protein transferase
10/23/1997WO1997034137A3 Methods of the identification of pharmaceutically active compounds
10/23/1997WO1997026918A3 Ligand directed enzyme prodrug therapy
10/23/1997WO1997026862A3 Improved concentrated injection and infusion solutions for intravenous administration
10/23/1997WO1997006659A3 Use of an eriobotrya japonica extract
10/23/1997DE19615232A1 Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten New carbamoyl derivatives and their use as 5-HT antagonists ¶1¶¶A¶
10/23/1997CA2251814A1 N-aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
10/23/1997CA2251716A1 Sensitization of cells to radiation and chemotherapy
10/23/1997CA2251384A1 Use of alkylaryl polyether alcohol polymers for the inhibition of nuclear transcription factor nf-xb
10/23/1997CA2251292A1 N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
10/23/1997CA2250943A1 Piperidinylpyrimidine derivatives
10/23/1997CA2249601A1 Inhibitors of farnesyl-protein transferase
10/23/1997CA2224859A1 Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
10/22/1997EP0802195A2 Substituted 2,3-benzodiazepine derivatives, process and intermediates for their preparation and pharmaceutical compositions comprising them as well as their use
10/22/1997EP0802183A1 Estrogenic agents
10/22/1997EP0801658A1 Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
10/22/1997EP0801648A1 Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof
10/22/1997EP0801644A1 Polyarylcarbamoylaza -and- carbamoylalkanedioic acids
10/22/1997EP0801574A1 Modulation of integrin-mediated signal transduction
10/22/1997EP0801572A2 Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin
10/22/1997EP0801568A1 Compounds for inhibition of ceramide-mediated signal transduction
10/22/1997EP0801567A1 1,3,3-(trisubstituted)cyclohex-1-ene monomers and related compounds
10/22/1997EP0801566A1 4,4-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds
10/22/1997EP0640080B1 Substituted indoles as angiotensin ii antagonists
10/22/1997CN1162977A Modified Factor VII
10/22/1997CN1162452A Luyoubao instant powder
10/22/1997CN1036200C Preparation of A-norsteroid-3-carboxylic
10/22/1997CN1036199C Erythromycin derivatives
10/21/1997US5679716 Administering xanthohumol
10/21/1997US5679712 Antiarrhythmia agents, treatment of cardiovascular, nervous system disorders
10/21/1997US5679700 Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
10/21/1997US5679691 Use of a spin trap in a cosmetic or dermatological composition
10/21/1997US5679685 Accelerated release composition containing bromocriptine
10/21/1997US5679677 Cardiovascular disorders
10/21/1997US5679668 Method of controlling fertility in males with 20-substitute of steroids
10/21/1997US5679658 N,O-carbonxymethylchitosan for prevention of surgical adhesions
10/21/1997US5679650 Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
10/21/1997US5679647 Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
10/21/1997US5679641 Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
10/21/1997US5679378 Method and material for hair therapy
10/21/1997US5679358 Formulations containing esculoside and the use thereof in the pharmaceutical and cosmetic fields
10/21/1997US5679339 Method of using IL-11 for treating spondyloarthropies
10/21/1997CA1339505C 2-substituted coumaran derivatives
10/21/1997CA1339502C Anti-cancer activity potentiator
10/16/1997WO1997038105A1 GENOMIC NUCLEIC ACIDS, cDNA AND mRNA WHICH CODE FOR POLYPEPTIDES WITH IL-16 ACTIVITY, PROCESSES FOR THE PRODUCTION THEREOF AND THEIR USE
10/16/1997WO1997038104A1 Il-6 mutein
10/16/1997WO1997038103A1 Il-6 mutein
10/16/1997WO1997038012A1 Extracellular/epidermal growth factor hcaba58x
10/16/1997WO1997038007A1 Peptidyl compounds having mmp and tnf- liberation inhibitory activity
10/16/1997WO1997038002A1 Extracellular/epidermal growth factor-like protein
10/16/1997WO1997037983A1 α1-ADRENERGIC RECEPTOR ANTAGONISTS
10/16/1997WO1997037979A1 New quinazoline-4-amino-2-(piperidine-1-yl-4-substituted) derivatives having anti-hypertensive activity, a method for their preparation and their pharmaceutical use
10/16/1997WO1997037974A1 Peptidyl compounds having mmp and tnf inhibitory activity
10/16/1997WO1997037973A1 Peptidyl compounds having mmp and tnf inhibitory activity
10/16/1997WO1997037688A2 Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
10/16/1997WO1997037681A1 Medicament for optimising mucosal viscosity and stimulating intestinal function
10/16/1997WO1997037665A1 Method of treating heart failure with endothelin antagonists
10/16/1997WO1997037658A1 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
10/16/1997WO1997037656A1 Anticachectic composition
10/16/1997WO1997037655A1 αvβ3 ANTAGONISTS
10/16/1997WO1997037645A1 Correction of genetic defects using chemical chaperones
10/16/1997WO1997024138A3 Medical use of proteases
10/16/1997WO1997022619A3 INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
10/16/1997DE19614099A1 Genomische Nukleinsäuren, die für Polypeptide mit IL-16-Aktivität codieren, Verfahren zu ihrer Herstellung und Verwendung Genomic nucleic acids, which encode polypeptides with IL-16 activity, processes for their preparation and use
10/16/1997CA2650637A1 Pharmaceutical composition containing angiotensin ii antagonist
10/16/1997CA2251569A1 Genomic nucleic acids, cdna and mrna which code for polypeptides with il-16 activity, processes for the production thereof and their use
10/16/1997CA2251308A1 New quinazoline-4-amino-2-(piperidine-1-yl-4-substituted) derivatives having anti-hypertensive activity, a method for their preparation and their pharmaceutical use
10/16/1997CA2251017A1 .alpha.v.beta.3 antagonists
10/16/1997CA2251009A1 Medicament for optimising mucosal viscosity and stimulating intestinal function
10/16/1997CA2250898A1 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
10/16/1997CA2250780A1 Correction of genetic defects using chemical chaperones
10/16/1997CA2250268A1 Extracellular/epidermal growth factor hcaba58x
10/16/1997CA2249213A1 Extracellular/epidermal growth factor-like protein
10/16/1997CA2248082A1 Peptidyl compounds having mmp and tnf- liberation inhibitory activity
10/16/1997CA2248070A1 Peptidyl compounds having mmp and tnf inhibitory activity
10/16/1997CA2247964A1 Peptidyl compounds having mmp and tnf inhibitory activity
10/15/1997EP0801132A2 Staphylococcal FtsH protein
10/15/1997EP0801067A1 Novel quinuclidine derivatives and medicinal composition thereof
10/15/1997EP0801060A1 Heterocyclic Beta-3 Adrenergenic Agonists
10/15/1997EP0800829A1 Antitumor agent potentiator comprising il-6 antagonist
10/15/1997EP0800826A2 Apoptosis-controlling agent
1 ... 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 ... 1564